LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P

Boon Shing Tan, Min Chi Yang, Shaifali Singh, Yu Chi Chou, Hsin Yi Chen, Ming Yang Wang, Yi-Ching Wang, Ruey Hwa Chen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Metastasis is responsible for most cancer mortality, but its molecular mechanism has not been completely understood. In addition to coding genes and miRNAs, the contribution of long noncoding RNAs (lncRNAs) to tumor metastatic dissemination and the mechanisms controlling their expression are areas of intensive investigation. Here, we show that lncRNA NORAD is downregulated in lung and breast cancers, and that NORAD low expression in these cancer types is associated with lymph node metastasis and poor prognosis. NORAD is transcriptionally repressed by the Hippo pathway transducer YAP/TAZ-TEAD complex in conjunction with the action of NuRD complex. Functionally, NORAD elicits potent inhibitory effects on migration and invasion of multiple lung and breast cancer cell lines, and repression of NORAD expression participates in the migration- and invasion-stimulatory effects of the YAP pathway. Mechanistically, NORAD exploits its multiple repeated sequences to function as a multivalent platform for binding and sequestering S100P, thereby suppressing S100P-elicited pro-metastatic signaling network. Using cell and mouse models, we show that the S100P decoy function of NORAD suppresses lung and breast cancer migration, invasion, and metastasis. Together, our study identifies NORAD as a novel metastasis suppressor, elucidates its regulatory and functional mechanisms, and highlights its prognostic value.

Original languageEnglish
Pages (from-to)5612-5626
Number of pages15
JournalOncogene
Volume38
Issue number28
DOIs
Publication statusPublished - 2019 Jul 11

Fingerprint

Lung Neoplasms
Long Noncoding RNA
Breast Neoplasms
Neoplasm Metastasis
Mi-2 Nucleosome Remodeling and Deacetylase Complex
Neoplasms
Transducers
MicroRNAs
Down-Regulation
Lymph Nodes
Cell Line
Mortality
Genes

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Tan, B. S., Yang, M. C., Singh, S., Chou, Y. C., Chen, H. Y., Wang, M. Y., ... Chen, R. H. (2019). LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene, 38(28), 5612-5626. https://doi.org/10.1038/s41388-019-0812-8
Tan, Boon Shing ; Yang, Min Chi ; Singh, Shaifali ; Chou, Yu Chi ; Chen, Hsin Yi ; Wang, Ming Yang ; Wang, Yi-Ching ; Chen, Ruey Hwa. / LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. In: Oncogene. 2019 ; Vol. 38, No. 28. pp. 5612-5626.
@article{8a3e75fd9d3b47809e52c2764b072677,
title = "LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P",
abstract = "Metastasis is responsible for most cancer mortality, but its molecular mechanism has not been completely understood. In addition to coding genes and miRNAs, the contribution of long noncoding RNAs (lncRNAs) to tumor metastatic dissemination and the mechanisms controlling their expression are areas of intensive investigation. Here, we show that lncRNA NORAD is downregulated in lung and breast cancers, and that NORAD low expression in these cancer types is associated with lymph node metastasis and poor prognosis. NORAD is transcriptionally repressed by the Hippo pathway transducer YAP/TAZ-TEAD complex in conjunction with the action of NuRD complex. Functionally, NORAD elicits potent inhibitory effects on migration and invasion of multiple lung and breast cancer cell lines, and repression of NORAD expression participates in the migration- and invasion-stimulatory effects of the YAP pathway. Mechanistically, NORAD exploits its multiple repeated sequences to function as a multivalent platform for binding and sequestering S100P, thereby suppressing S100P-elicited pro-metastatic signaling network. Using cell and mouse models, we show that the S100P decoy function of NORAD suppresses lung and breast cancer migration, invasion, and metastasis. Together, our study identifies NORAD as a novel metastasis suppressor, elucidates its regulatory and functional mechanisms, and highlights its prognostic value.",
author = "Tan, {Boon Shing} and Yang, {Min Chi} and Shaifali Singh and Chou, {Yu Chi} and Chen, {Hsin Yi} and Wang, {Ming Yang} and Yi-Ching Wang and Chen, {Ruey Hwa}",
year = "2019",
month = "7",
day = "11",
doi = "10.1038/s41388-019-0812-8",
language = "English",
volume = "38",
pages = "5612--5626",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "28",

}

LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. / Tan, Boon Shing; Yang, Min Chi; Singh, Shaifali; Chou, Yu Chi; Chen, Hsin Yi; Wang, Ming Yang; Wang, Yi-Ching; Chen, Ruey Hwa.

In: Oncogene, Vol. 38, No. 28, 11.07.2019, p. 5612-5626.

Research output: Contribution to journalArticle

TY - JOUR

T1 - LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P

AU - Tan, Boon Shing

AU - Yang, Min Chi

AU - Singh, Shaifali

AU - Chou, Yu Chi

AU - Chen, Hsin Yi

AU - Wang, Ming Yang

AU - Wang, Yi-Ching

AU - Chen, Ruey Hwa

PY - 2019/7/11

Y1 - 2019/7/11

N2 - Metastasis is responsible for most cancer mortality, but its molecular mechanism has not been completely understood. In addition to coding genes and miRNAs, the contribution of long noncoding RNAs (lncRNAs) to tumor metastatic dissemination and the mechanisms controlling their expression are areas of intensive investigation. Here, we show that lncRNA NORAD is downregulated in lung and breast cancers, and that NORAD low expression in these cancer types is associated with lymph node metastasis and poor prognosis. NORAD is transcriptionally repressed by the Hippo pathway transducer YAP/TAZ-TEAD complex in conjunction with the action of NuRD complex. Functionally, NORAD elicits potent inhibitory effects on migration and invasion of multiple lung and breast cancer cell lines, and repression of NORAD expression participates in the migration- and invasion-stimulatory effects of the YAP pathway. Mechanistically, NORAD exploits its multiple repeated sequences to function as a multivalent platform for binding and sequestering S100P, thereby suppressing S100P-elicited pro-metastatic signaling network. Using cell and mouse models, we show that the S100P decoy function of NORAD suppresses lung and breast cancer migration, invasion, and metastasis. Together, our study identifies NORAD as a novel metastasis suppressor, elucidates its regulatory and functional mechanisms, and highlights its prognostic value.

AB - Metastasis is responsible for most cancer mortality, but its molecular mechanism has not been completely understood. In addition to coding genes and miRNAs, the contribution of long noncoding RNAs (lncRNAs) to tumor metastatic dissemination and the mechanisms controlling their expression are areas of intensive investigation. Here, we show that lncRNA NORAD is downregulated in lung and breast cancers, and that NORAD low expression in these cancer types is associated with lymph node metastasis and poor prognosis. NORAD is transcriptionally repressed by the Hippo pathway transducer YAP/TAZ-TEAD complex in conjunction with the action of NuRD complex. Functionally, NORAD elicits potent inhibitory effects on migration and invasion of multiple lung and breast cancer cell lines, and repression of NORAD expression participates in the migration- and invasion-stimulatory effects of the YAP pathway. Mechanistically, NORAD exploits its multiple repeated sequences to function as a multivalent platform for binding and sequestering S100P, thereby suppressing S100P-elicited pro-metastatic signaling network. Using cell and mouse models, we show that the S100P decoy function of NORAD suppresses lung and breast cancer migration, invasion, and metastasis. Together, our study identifies NORAD as a novel metastasis suppressor, elucidates its regulatory and functional mechanisms, and highlights its prognostic value.

UR - http://www.scopus.com/inward/record.url?scp=85064070329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064070329&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0812-8

DO - 10.1038/s41388-019-0812-8

M3 - Article

VL - 38

SP - 5612

EP - 5626

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 28

ER -